Asset
VEBRELTINIB
Apollomics Inc. Class A Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05367388 | phase1 | unknown | 2022-05-20 | 2022-11-01 | Apollomics Inc. | A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants |
FDA applications (0)
This company has no applications containing this asset.